Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

BMC Pulm Med. 2021 Jun 8;21(1):193. doi: 10.1186/s12890-021-01559-7.

Tang-Hsiu Huang^{1

2}, Chin-Wei Kuo^{1

2}, Chian-Wei Chen¹, Yau-Lin Tseng³, Chao-Liang Wu⁴, Sheng-Hsiang Lin^{5

6

7}

¹ Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
² Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
³ Division of Thoracic Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁴ Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁵ Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. shlin922@mail.ncku.edu.tw.
⁶ Department of Public Health, College of Medicine, National Cheng-Kung University, Tainan, Taiwan. shlin922@mail.ncku.edu.tw.
⁷ Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng-Kung University, Tainan, Taiwan. shlin922@mail.ncku.edu.tw.

No abstract available

Publication types